Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 5/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 3/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9105667 | 0.91 | PLA2G7 (0.62) | PLA2G7GPR84RAF1BRAF | |
| SCHEMBL9234987 | 0.88 | PLA2G7 (0.44) | PLA2G7GPR84PPARGPPARAKDM4E | |
| SCHEMBL9104009 | 0.88 | PLA2G7 (0.56) | PLA2G7GPR84PPARGPPARAKDM4E | |
| SCHEMBL9107934 | 0.85 | PLA2G7 (0.42) | PLA2G7GPR84PPARGPPARAKDM4E | |
| SCHEMBL9108449 | 0.84 | PLA2G7 (0.41) | PLA2G7 | |
| SCHEMBL9889433 | 0.84 | PLA2G7 (0.59) | PLA2G7GPR84RAF1BRAF | |
| SCHEMBL9103285 | 0.84 | PLA2G7 (0.59) | PLA2G7GPR84RAF1BRAF | |
| SCHEMBL9106542 | 0.83 | PLA2G7 (0.41) | PLA2G7GPR84PPARGPOLB | |
| Gsk-2647544 SCHEMBL9104177 | 0.83 | PLA2G7 (0.73) | PLA2G7GPR84RAF1BRAF | |
| SCHEMBL9889667 | 0.83 | PLA2G7 (0.42) | PLA2G7GPR84PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-8637536-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-01-28 | — | — | US | disclosed |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142717-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | PLA2G7 6/4885GPR84 742/4885PPARG 679/4885 |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | PLA2G7 4/4885GPR84 446/4885PPARG 585/4885 |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | PLA2G7 4/4885GPR84 403/4885PPARG 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.